Establishment Labs Holdings Inc. (ESTA) recently announced that it has secured approval from the U.S. Food and Drug Administration (FDA) for its Motiva SmoothSilk Ergonomix and Motiva SmoothSilk Round breast implants, intended for use in both primary and revision breast augmentation procedures.
The company highlighted that the Motiva SmoothSilk Round and Ergonomix Implants exemplify the latest advancements in plastic surgery. These implants incorporate the patented SmoothSilk surface, which is engineered for superior biocompatibility and scientifically verified to support low inflammation.
This approval marks the first new breast implant Premarket Approval (PMA) by the U.S. FDA since 2013.
On Thursday, ESTA's stock closed at $41.19, up $1.29 or 3.25%. During after-hours trading, the stock saw an additional rise of $9.85 or 23.92%.
